Combining AI and high throughput screening for effective protein drugs.
External link for Vcreate
Excited to catch up with advisors and partners at JPM next week! Ron Alfa, MD, PhD Hanadie Yousef Richard Yu Camella Wilson, PhD Ahmet Hamdi C.
Happy to share that Vcreate recently recieved a Phase II NSF SBIR Award (up to $2M in non-dilutive grants) to help fund our AI platform for cancer drug discovery. We are excited to advance our programs in 2025. Thanks to our amazing team, advisors, and partners for all your support along the way!
Looking forward to connecting with the IO community.
I am presenting at Society for Immunotherapy of Cancer (SITC) 2024 Meeting in Houston this week (Poster 1095). Reach out if you want to chat about T-cell engagers, protein design and lead optimization. Abstract: https://lnkd.in/g2DWmsyW #sitc2024
See you in Houston! #SITC2024
Excited to present Vcreate’s protein design and immunotherapy work at the 2024 Society for Immunotherapy of Cancer (SITC) Annual Meeting and its Immune Engineering Workshop. Would you believe that machine learning can improve the potency (EC50) of a protein receptor by 100 folds, selecting and testing only 20 variants? Reach out and we would love to tell you more. #SITC2024 #Abstract1095 #Houston #AI #proteindesign #immunotherapy Ethan Fast Manjima Dhar
Keep building!
Thanks to Merck Digital Science Studio for their support over the past ten months. We are grateful for the opportunity to connect with so many amazing founders, scientists, and investors all along the way. Sample pictures from our final demo day. Excited to meet our cohort 3 in the future! Ahmet Hamdi C. Geof Hannigan, PhD Anita Manik, MBA, CPA Juan Alvarez Camella Wilson, PhD Prem Tumkosit, Carrie Williams, Northpond Ventures Microsoft for Startups Merck Global Health Innovation Fund, NJIT
We are excited to welcome Jonathan Schneck MD/PhD, Professor at Johns Hopkins Medicine and co-founder of NexImmune Inc. (NASDAQ: NEXI), to the Scientific Advisory Board of Vcreate. A pioneer in T cell biology, Dr. Schneck has developed crucial technologies such as artificial antigen presenting cells and artificial lymph nodes for advanced cancer immunotherapy. Technologies from the Schneck Lab enable the field to better activate and engineer anti-cancer T cells in vivo. We look forward to working with Dr. Schneck to advance our platform and build our asset portfolio. Dr. Schneck will join our other amazing advisors, including Russ Altman Eric Horvitz Lisa Wagar Michael Khodadoust Richard Yu Hanadie Yousef Gunsagar Gulati Ron Alfa, MD, PhD